BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25851862)

  • 1. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
    Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
    Zhang H; Yang X; Zheng F; Wan S; Xu Y
    Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
    Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
    J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
    Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
    Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
    Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
    Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
    Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
    Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
    Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
    Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.